THE WHAT? Beiersdorf has announced that it has purchased a majority stake in Belgian life science firm, S-Biomedic. The German owner of Nivea has invested in the skin microbiome specialist previously as part of its corporate venture capital activities. The purchase price was not disclosed.
THE DETAILS The collaboration between the two companies will become closer following the deal with S-Biomedic managed as a standalone entity under Beiersdorf’s existing microbiome program.
THE WHY? Dr Gitta Neufang, Senior Vice President of Research & Development at Beiersdorf, explains, “As skin care experts, research has been at the heart of what we have been doing for 140 years. Therefore, the acquisition of S-Biomedic is an ideal strategic fit to drive our innovation power even further in line with our C.A.R.E.+ strategy. Together with the pioneers of S-Biomedic we are taking skin care to the next level and will foster the development of solutions for unmet consumer needs.”